About three years ago, Stephanie Donati of DuBois was busy prepping her yard and outdoor furniture for the coming winter. But the aches and pains from her chores wouldn’t go away.

Her doctor first suspected a urinary tract infection because of the lingering abdominal discomfort she reported, but it was quickly ruled out. The physician next considered gallbladder issues and ordered an ultrasound.

The murky films were inconclusive, and another doctor suggested a CT scan. Just two hours after the scan, the radiologist called, telling her, “You need to get a hold of your gynecologist,” Donati’s husband, Ray, remembered.

Her ovaries were alarmingly enlarged. And cancerous.

Advertise with us

For many women, ovarian cancer begins quietly — with subtle, almost dismissible symptoms — until it reveals itself in devastating fashion. By the time it’s diagnosed, the disease is frequently advanced, leaving patients with fewer treatment options and lower survival rates.

Ovarian cancer is very treatable when caught early, but most cases — about 75% of them — are not diagnosed until it’s too late, according to Johns Hopkins Medicine. By the time patients become symptomatic, they have advanced-stage disease in approximately 75–80% of cases.

But newer, more personalized therapies — like inhibitors that attack cancer cell DNA, conjugates that can deliver chemotherapy drugs directly to cancer cells, and blockers that prevent tumor blood vessels from growing — paired with traditional chemotherapy are giving women with ovarian cancer better outcomes.

Within a few weeks of Donati’s diagnosis, Eirwen Miller, a gynecological oncologist at Allegheny Health Network, had mapped out a treatment plan that began with surgery. Once in the operating room, however, the diagnosis took a sobering turn: advanced, unresectable Stage 4 ovarian cancer.

“When I opened [Stephanie’s] belly, she had so much more disease than what was suggested by her scan. And that really changed the course of her treatment,” Miller said.

Advertise with us

Donati’s cancer was scattered throughout her abdomen, in a pattern called carcinomatosis, a condition where cancer cells spread widely throughout the body, often forming multiple small tumors in various organs. It is a serious and advanced stage of cancer that typically indicates a poor prognosis, per the National Cancer Institute, part of the NIH.

“Think about your belly as a sandbox, and if you took a handful of rice and threw it in the sandbox, you would get just these small little grains or implants of cancer kind of just scattered throughout the belly,” Miller explained. “And sometimes those grains can become confluent with one another, and you get larger implants.”

Trying to find and remove all those tiny cancerous cells would have been virtually impossible. Additionally, trying to operate at that stage could have meant removing critical portions of Donati’s bowel and still not eliminating all the cancer.

So instead of surgery, Donati was stitched up and sent right to recovery. Chemotherapy would have to come first; surgery would follow later.

After three rounds of chemotherapy, Donati underwent a total hysterectomy.

Advertise with us

She had a “phenomenal response” to the chemotherapy, Miller said, so that the cancer spotted in the first surgery, “melted almost completely away by the time we went back for her second surgery, to the point that all of the metastatic cancer that she had through her belly was gone, and she only had microscopic cancer left in her ovaries and fallopian tubes.”

It was a powerful response to treatment shaped by Donati’s BRCA2 mutation that caused the cancer.

Women with a BRCA gene mutation have a dramatically increased risk for both ovarian and breast cancers, according to the U.S. Centers for Disease Control and Prevention. About half of those with the mutation will develop breast cancer, and about 30% will develop ovarian cancer by age 70, compared to 7% and 1%, respectively, in the general population.

Stephanie Donati wore cooling mittens and booties during her chemotherapy sessions to reduce the chance of developing neuropathy. (Courtesy of Stephanie Donati)

Subtle symptoms

Like many patients, Donati experienced the hallmark but subtle signs of ovarian cancer: decreased appetite, pelvic pressure, a little nausea.

But these symptoms are vague and certainly not specific to only ovarian cancer, Miller pointed out.

Advertise with us

“So people can have those symptoms for a really long time before they're having an evaluation that identifies their malignancy and their ovarian mass,” Miller said.

On average, she noted, patients like Donati have symptoms for about three months before a diagnosis is made.

For Donati, that lack of awareness is part of what she now wants other women to understand.

“It's just not common. It's not known. I want people to be aware of it. Talk to their gynecologists about it. I had to tell all my sisters and my nieces about it so that then, they could watch for these symptoms,” Donati said.

The bigger challenge, Miller said, is that ovarian cancer lacks a reliable screening tool.

Advertise with us

“For cervical cancer, we have an incredibly effective screening test in the Pap smear. We have prevention for cervical cancer with the HPV vaccine. We have great screening for breast cancer. … But for ovarian cancer, we don't have an accurate screening test.”

While the standard chemotherapy for ovarian cancer has not changed much in decades, maintenance strategies and supportive care have evolved rapidly, she said.

“Maintenance therapy” has vastly improved in the last 10 years, she said. “A lot of those approaches are targeted, so looking at biomarkers in a patient's cancer or in their own genetics to help guide … what the most effective maintenance strategy might be.”

After surgery, Donati completed three more rounds of chemotherapy to attack microscopic cells. For the past two years, she has taken an oral maintenance therapy, known as a PARP inhibitor. She finished the final dose at the end of August.

PARP inhibitors are a targeted therapy that blocks enzymes in cells called PARP, which the body uses to repair damaged DNA. In cancer treatment, blocking PARP is intended to stop cancer cells from repairing their damaged DNA, eventually killing off the cells, according to the National Cancer Institute.

Advertise with us

The treatment has been found to be particularly effective for those with the BRCA mutation. Miller said patients with the BRCA gene “are about 50% less likely to die of their cancer if they get a PARP inhibitor than if they don't.”

Advances in anti-nausea and fatigue medications have also made chemotherapy more tolerable.

“It's actually pretty rare now that I have patients come to me and say, ‘I'm debilitated by my nausea, or I'm debilitated by my fatigue,’” Miller said.

Looking ahead, she is optimistic about the role of antibody drug conjugates, an emerging class of personalized medicine therapies being studied in AHN clinical trials.

“These are likely to really change our standard of care going forward,” Miller said.

Advertise with us

For women at high risk of ovarian cancer, including those with BRCA mutations, Miller said the most effective prevention remains surgical removal of the ovaries and fallopian tubes, ideally before menopause.

“These are life-saving surgeries,” she said. “If someone said to you, the risk that you're going to get ovarian cancer in your lifetime is 40% and if you get it, there's a high likelihood that this is a fatal diagnosis. I think most women would elect to take their tubes and ovaries out.”

Such procedures also reduce the risk of breast cancer by 50% in women with BRCA mutations, Miller noted.

Now 70 years old, Donati is enjoying retirement, traveling with her husband and living with no evidence of disease.

“Her husband is just like the strong pillar with her. They're amazing,” Miller added.